03 Feb 03
Four major brands, TAP’s Lupron, AstraZeneca’s Zoladex, Nolvadex and Casodex, account for 49% of the total value of the anti-hormonals market at present. The loss of patent protection for these compou
03 Feb 03
Over the past fortnight the Internet has benefited from Healthcare initiatives with a number of online health information tools being launched in particular. Schering-Plough led the way on this front but the leading pharmaceuticals were not all so happy. GlaxoSmithKline, for example, recently received criticism over its threat to stop supplying drugs to Canadian online pharmacies. These stories and others are covered in detail in this week’s eHealth News Roundup.
03 Feb 03
Lung cancer is one of the most prevalent forms of cancer to afflict both men and women, accounting for nearly 15% of all cancer cases. The size of the lung cancer market - estimated at $1.6bn in 2002
13 Jan 03
During the last year bioterrorism has attracted a high level of media and clinical attention. However, this publicity does not necessarily reflect a potential opportunity for easy market entry or high
17 Dec 02
The number of people with chronic heart failure in the western world is increasing so rapidly that, according to Datamonitor's EpiVision forecasts, by 2015 there will be 1.5 million sufferers in the UK alone. Although this is small in comparison to the 8.2 million already suffering from the condition in the US, the problem is great enough to represent a real danger for the already beleaguered NHS.
13 Dec 02
As the medical device field becomes more advanced the need for clinical trials will grow. With less experience of global clinical trials than those in the pharmaceutical sector, medical device compani
Dr Faiz Kermani and Jeff Kingston
06 Dec 02
According to new research pharmaceutical companies are investing more than ever to promote their drugs. Growth in promotional investment is thought to be increasing at a faster rate than growth in ethical sales. With this trend unlikely to continue because of economic constraint can the drug companies increase the impact of their marketing or do they face the prospect of slashing expenditure?
03 Dec 02
The healthcare industry is increasingly looking to take advantage of the Internet and one of the leading pharmaceutical groups is leading the way. Schering-Plough has recognized the potential benefit
22 Nov 02
Patient enrollment is of continued interest, as many companies believe it is possible to improve clinical cycle times by compressing the enrolment period. However, this means recognizing the fact that the nature of the trial will affect the recruitment period and so the degree of improvement that can be made will differ from trial to trial.
Pietro Bonacossa and Faiz Kermani
08 Nov 02
Since the mid-1990s there has been a near exponential rise in the level of glycogen synthase kinase-3 (GSK-3) related research. Consequently the therapeutic potential of GSK-3 inhibitors has become a
Dr Jon Goldhill
07 Nov 02
PiR Group has released the essential guide to Qualified Persons (QP) salary and benefits - The 2002 QP Salary Survey & Report. The data reveals that there is no longer a 'north/south divide' but more
29 Oct 02
Your relationship with recruitment agencies and consultants is of critical importance if you are to quickly secure employment. This article will help you to better understand the dynamics of this rela
25 Oct 02
LeadDiscovery is pleased to announce the completion of it's most recent DiscoveryDossier describing a new licensing or co-development opportunity relating the treatment of erectile dysfunction and fem
Dr Jon Goldhill
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.